Trametinib is a reversible and highly selective allosteric MEK1/MEK2 inhibitor, with an indication for the treatment of different solid tumors characterized by MAPK signaling pathway alterations, such as advanced melanoma [115] or low-grade gliomas [116]. Here, MAP2K1 is linked to central nervous system cancer.